Disappointing results of olesoxime clinical trial announced
13 December 2011 Results from a recent clinical trial into motor neurone disease (MND), involving people with MND in England, have been announced and show the trial drug to be ineffective a
The information provided in this web site is intended to educate the reader about certain medical conditions and certain possible treatments. It is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. If you believe you, suffer from the conditions described herein, please see your health care provider. Do not attempt to treat yourself or anyone else without proper medical supervision.
Read the Full Disclaimer
Page 1 of 2 Next
News
Trophos announces results of phase 3 study of olesoxime in ALS
MARSEILLE, FRANCE – December 13 2011. Trophos SA announces today the results from the phase 3 study of Trophos’ lead compound, olesoxime, in 512 patients with ALS.
Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease)
Top-line results expected fourth quarter 2011 Marseille, France, September 22, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discov
Trophos and the MitoTarget Consortium demonstrate potential of modulating mitochondrial dysfunction in the treatment of neurodegenerative diseases
Presentations at the Society for Neuroscience congress also focus on underlying mechanisms of neuronal cell metabolism and death Marseille, France, November 18, 2010 - Trophos SA, a clinical s
Actelion joins forces with Trophos to further advance olesoxime to the market once results of the MitoTarget clinical study are known.
Actelion obtains option to acquire privately-held Trophos Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be furth
